4.7 Article

Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 27, Issue 2, Pages 371-379

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2015030261

Keywords

-

Funding

  1. AM-Pharma (Amsterdam, The Netherlands)
  2. Abbott Laboratories (Chicago, IL)
  3. Alere (San Diego, CA)
  4. Alung (Pittsburgh, PA)
  5. Astute Medical (San Diego, CA)
  6. Atox Bio (Ness Ziona, Israel)
  7. Baxter (Chicago, IL)
  8. Cytosorbents (Princeton, NJ)
  9. Grifols (Barcelona, Spain)
  10. Roche (Basel, Switzerland)
  11. Spectral Diagnostics (Toronto, Canada)
  12. Bard (Covington, GA)
  13. Grants-in-Aid for Scientific Research [26111003] Funding Source: KAKEN

Ask authors/readers for more resources

Inflammation is a complex biologic response that is essential for eliminating microbial pathogens and repairing tissue after injury. AKI associates with intrarenal and systemic inflammation; thus, improved understanding of the cellular and molecular mechanisms underlying the inflammatory response has high potential for identifying effective therapies to prevent or ameliorate AKI. In the past decade, much knowledge has been generated about the fundamental mechanisms of inflammation. Experimental work in small animal models has revealed many details of the inflammatory response that occurs within the kidney after typical causes of AKI, including insights into the molecular signals released by dying cells, the role of pattern recognition receptors, the diverse subtypes of resident and recruited immune cells, and the phased transition from destructive to reparative inflammation. Although this expansion of the basic knowledge base has increased the number of mechanistically relevant targets of intervention, progress in developing therapies that improve AKI outcomes by modulation of inflammation remains slow. In this article, we summarize the most important recent developments in understanding the inflammatory mechanisms of AKI, highlight key limitations of the commonly used animal models and clinical trial designs that may prevent successful clinical application, and suggest priority approaches for research toward clinical translation in this area.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available